A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly

ConclusionsClinical efficacy/effectiveness, safety, and HRQoL outcomes in adults with acromegaly were similar and costs lower with EDIs versus standard regimens. Physicians may consider acromegaly treatment at EDIs, especially for patients with good disease control.

http://link.springer.com/10.1007/s11102-022-01285-1

Source: Pituitary - February 1, 2023 Category: Endocrinology Source Type: research